Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Higuchi T, Kawaguchi K, Miyake K, Han Q, Tan Y, Oshiro H, Sugisawa N, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Singh AS, Eilber FC, Singh SR, Tsuchiya H, Hoffman RM
Anticancer research · 39 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Animal study (classified by our AI screen)
- Studied in
- Animals
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2018-10-01 · Anticancer Res · vol. 38 · issue 10 · pp. 5639–5644
- Publisher
- International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts
- Cited
- 75 citations · more than 98% of similar papers · 6.2× the field average
- Impact
- Top 10% most cited in its field
- References
- 26 works
- Access
- Free to read
- Research areas
- Cancer Research and Treatments · Virus-based gene therapy research · Photodynamic Therapy Research Studies
- Keywords
- Doxorubicin, Recombinant DNA, Synovial sarcoma, Sarcoma, Caffeine, Cancer research, Pharmacology, Biology, Medicine, Chemotherapy, Chemistry, Internal medicine, Biochemistry, Pathology, Gene
- MeSH
- tumor cells, cultured, animals, humans, mice, mice, nude, sarcoma, synovial, caffeine, doxorubicin, carbon-sulfur lyases, recombinant proteins, central nervous system stimulants, antibiotics, antineoplastic, combined modality therapy, administration, oral, xenograft model antitumor assays, drug resistance, neoplasm, middle aged, male
20 authors
From JP, US
- Takashi HiguchiKanazawa University; University of California San Diego; AntiCancer (United States)
- Kei KawaguchiUniversity of California San Diego; AntiCancer (United States)
- Kentaro MiyakeUniversity of California San Diego; AntiCancer (United States)
- Qinghong HanAntiCancer (United States)
- Yuying TanAntiCancer (United States)
- Hiromichi OshiroUniversity of California San Diego; AntiCancer (United States)
Abstract
Background/aim
Synovial sarcoma (SS) is a recalcitrant neoplasm with low chemosensitivity. We recently reported that recombinant methioninase (rMETase) inhibited SS growth in a patient-derived orthotopic xenograft (PDOX) mouse model and was more effective when administered in combination with the first-line drug doxorubicin (DOX). Caffeine enhances the efficacy of anticancer drugs by overcoming drug-induced cell-cycle arrest and increasing subsequent apoptosis. Here, we determined the efficacy of oral recombinant methioninase (o-rMETase) in combined with caffeine on an SS-PDOX model.
Materials and methods
Mice bearing SS-PDOX tumors were randomized into four treatment groups of six: Untreated control; o-rMETase alone; o-rMETase with caffeine; DOX plus o-rMETase with caffeine. Tumor size and body weight were measured during the treatment and plasma L-methionine (MET) levels were measured at the end of treatment.
Results
All treatments significantly inhibited SS-PDOX tumor growth. Combining caffeine with o-rMETase was more effective than o-rMETase alone. DOX combined with o-rMETase and caffeine led to regression of SS-PDOX. Plasma MET levels were reduced with o-rMETase treatment.
Conclusion
These results suggest that combining o-rMETase and caffeine along with first-line chemotherapy can be highly effective for SS and has clinical potential for this recalcitrant disease.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.